NCNA
NuCana plc NASDAQ Listed Sep 28, 2017$1.21
+2.99%
vs $1.17
Mkt Cap $7.3M
52w Low $1.01
3.1% of range
52w High $7.22
50d MA $1.39
200d MA $2.01
P/E (TTM)
—
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.0x
ROE
—
P/FCF
-0.6x
RSI (14)
36.80
ATR (14)
$0.10
Beta
1.80
50d MA
$1.39
200d MA
$2.01
Avg Volume
202.6K
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
3 Lochside Way · Edinburgh, X0 EH12 9DT · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | AMC | -2.65 | -0.99 | +62.7% | 1.48 | +0.7% | +7.4% | -2.5% | -1.9% | +2.0% | -1.3% | — |
| May 14, 2026 | AMC | -2.64 | -1.25 | +52.7% | 1.98 | +2.5% | +10.1% | -6.9% | -2.5% | +3.0% | -0.5% | — |
| Mar 19, 2026 | AMC | -2.69 | -1.47 | +45.4% | 1.71 | -0.6% | -3.5% | +0.6% | -4.2% | -3.8% | -3.3% | — |
| Nov 13, 2025 | AMC | -2.69 | -0.10 | +96.3% | 3.49 | -7.2% | -2.3% | -6.2% | +3.4% | +1.2% | +6.3% | — |
| Aug 20, 2025 | AMC | -2.75 | -0.16 | +94.2% | 3.11 | +7.1% | +6.4% | +3.9% | -1.2% | -1.2% | -3.6% | — |
| Jun 2, 2025 | AMC | -2.58 | -126.00 | -4778.0% | 7.60 | +15.0% | +57.4% | -22.9% | -14.3% | +26.3% | +52.7% | — |
| Mar 20, 2025 | AMC | -486.00 | -64.00 | +86.8% | 161.40 | -0.8% | -2.2% | +0.1% | +1.3% | +3.8% | +28.9% | — |
| Nov 25, 2024 | AMC | -3.47 | -456.00 | -9999.0% | 252.00 | +0.8% | +5.6% | -3.0% | +0.8% | -3.1% | -0.8% | — |
| Aug 15, 2024 | AMC | -710.00 | -758.00 | -6.8% | 658.00 | +0.6% | +6.4% | +177.1% | -12.3% | +2.5% | -7.8% | — |
| May 16, 2024 | AMC | -662.00 | -32.00 | +95.2% | 734.00 | +3.3% | -2.7% | +0.8% | -4.2% | +4.1% | -1.9% | — |
| Mar 20, 2024 | AMC | -650.00 | -850.00 | -30.8% | 1664.00 | +2.2% | -13.0% | +5.0% | +3.3% | -2.5% | +0.3% | — |
| Nov 16, 2023 | AMC | -650.00 | -800.00 | -23.1% | 2102.00 | -2.5% | +1.7% | -2.8% | -1.3% | +11.2% | +6.9% | — |
| Aug 16, 2023 | AMC | -800.00 | -650.00 | +18.8% | 3550.00 | +1.4% | +9.9% | -3.8% | -2.7% | -1.4% | +1.3% | — |
| May 17, 2023 | AMC | -600.00 | -900.00 | -50.0% | 3798.00 | -1.3% | -2.6% | +0.7% | +20.8% | +0.0% | -5.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19 | Oppenheimer | Maintains | Outperform → Outperform | — | $700.00 | $700.00 | +0.0% | +177.1% | -12.3% | +2.5% | -7.8% | -11.8% |
| Jul 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $622.00 | $608.00 | -2.3% | +23.2% | -8.4% | +2.6% | +5.6% | -5.3% |
| Jul 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $596.00 | $636.00 | +6.7% | +4.4% | +23.2% | -8.4% | +2.6% | +5.6% |
| Apr 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $1300.00 | $1240.00 | -4.6% | -8.8% | -3.0% | +14.1% | -8.8% | -2.7% |
| Nov 21 | Oppenheimer | Maintains | Outperform → Outperform | — | $2078.00 | $2078.00 | +0.0% | -1.3% | +11.2% | +6.9% | +0.2% | -3.8% |
| Sep 6 | Truist | Maintains | Buy → Buy | — | $3282.00 | $3200.00 | -2.5% | +1.3% | -4.9% | -2.0% | +3.9% | -3.9% |
| Aug 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $3900.00 | $3896.00 | -0.1% | -3.8% | -2.7% | -1.4% | +1.3% | +0.8% |
| May 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $3726.00 | $3650.00 | -2.0% | +20.8% | +0.0% | -5.5% | -5.9% | +6.2% |
| Sep 22 | Jefferies | Maintains | Buy → Buy | — | $7000.00 | $6800.00 | -2.9% | -18.6% | -13.6% | +2.6% | -3.5% | +2.6% |
| Mar 3 | TD Cowen | Downgrade | Outperform → Market Perform | — | $14700.00 | $6150.00 | -58.2% | -59.2% | -20.5% | -15.4% | -8.7% | +13.9% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13150.00 | $13150.00 | +0.0% | +8.0% | -1.1% | -0.7% | -2.2% | -4.9% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22800.00 | $23750.00 | +4.2% | +0.0% | +0.4% | +2.6% | +0.4% | -1.7% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23350.00 | $23350.00 | +0.0% | -2.6% | -2.0% | +0.9% | +1.3% | +0.0% |
| Oct 22 | Truist | Maintains | Buy → Buy | — | $25300.00 | $27300.00 | +7.9% | +9.9% | +0.5% | -2.5% | -1.8% | -6.7% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26550.00 | $27350.00 | +3.0% | +3.6% | +2.8% | -1.7% | -4.1% | -0.9% |
| Jul 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $25750.00 | $27550.00 | +7.0% | +8.9% | -2.0% | -2.9% | -3.1% | +1.3% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33800.00 | $33800.00 | +0.0% | -6.2% | -14.5% | +6.1% | -5.2% | +3.9% |
| Mar 11 | H.C. Wainwright | Maintains | Buy → Buy | — | $33800.00 | $33800.00 | +0.0% | -6.2% | -14.5% | +6.1% | -5.2% | +3.9% |
| Nov 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $27750.00 | $27050.00 | -2.5% | +7.9% | +8.3% | +4.2% | +0.4% | -1.5% |
| Aug 19 | H.C. Wainwright | Maintains | Buy → Buy | — | $34750.00 | $36250.00 | +4.3% | +5.3% | +9.3% | -3.1% | -2.3% | +1.1% |
| Oct 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $85950.00 | $91600.00 | +6.6% | +18.1% | -10.8% | -6.8% | +4.2% | -7.1% |
| Oct 23 | Citigroup | Maintains | Buy → Buy | — | $70400.00 | $71700.00 | +1.8% | -1.2% | -0.8% | -6.7% | -3.0% | +0.0% |
| Oct 23 | TD Cowen | Maintains | Outperform → Outperform | — | $70400.00 | $71700.00 | +1.8% | -1.2% | -0.8% | -6.7% | -3.0% | +0.0% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 9
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 54,198 | $82K | Added | Jun 2026 |
| 2 | Jane Street Group, Llc | 11,330 | $41K | Reduced | Dec 2025 |
| 3 | Glass Jacobson Investment Advisors Llc | 15,000 | $23K | — | Jun 2026 |
| 4 | Rhumbline Advisers | 4,698 | $7K | New | Jun 2026 |
| 5 | Morgan Stanley | 210 | $756 | Added | Dec 2025 |
| 6 | Citigroup Inc | 188 | $286 | Reduced | Jun 2026 |
| 7 | Caitong International Asset Management Co., Ltd | 5 | $8 | New | Jun 2026 |
| 8 | Sbi Securities Co., Ltd. | 1 | $2 | New | Jun 2026 |
| 9 | Acadian Asset Management Llc | 2 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 1
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Blackstone Alternative Multi-Strategy Fund | -271 | $-412 | Jun 2026 |
Valuation
Market Cap
$7.3M
Enterprise Value
-$19.9M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.18x
P/S
—
P/FCF
-0.62x
EV/EBITDA
—
Shares Out
3.7M
Financials (TTM)
Revenue
$0
Net Income
-$9.7M
EBITDA
-$14.4M
Free Cash Flow
-$7.0M
Op Cash Flow
-$7.0M
EPS Basic
$-7.75
EPS Diluted
$-2.97
EPS Forward
$-8.21
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$29.8M
Total Liab.
$5.5M
Total Equity
$24.3M
Cash
$24.2M
LT Debt
$0
Book Value/Sh
$6.57
Debt/Equity
0.03x
Current Ratio
5.60
Quick Ratio
5.60
Returns & Growth
ROE
—
ROA
—
ROIC
-78.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
-137.1%
Price Returns
2W
-12.0%
1M
-15.8%
3M
-14.0%
6M
-28.2%
12M
-74.7%
Technicals
52W High
$7.22
52W Low
$1.01
50d MA
$1.39
200d MA
$2.01
RSI (14)
36.80
ATR (14)
$0.10
Beta
1.80
Avg Volume
203K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 2:29pm
· Source: financialmodelingprep.com